Lowy: COVID-19 pandemic inspired new “shortcuts” in NCI clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Our full coverage of SARS-CoV2 is available here.

Adjusting to the pandemic, NCI has developed shortcuts in the conduct of clinical trials that could make it easier to conduct clinical trials, NCI Principal Deputy Director Douglas Lowy said at the virtual meeting of the American Association for Cancer Research on COVID-19 and Cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
Alexandria Carolan
Alexandria Carolan
Reporter

Login